Adrenergic Modulation of Melanoma Cells Proliferation

Surcel, Mihaela

doi:10.31925/farmacia.2018.5.11

Cited by 7 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This could be the first study, which other researchers and clinicians can use and analyze in order to evaluate the influence of different melanoma treatments on antiganglioside antibodies. The pathogenic mechanisms involved in melanoma are complex [ 53 – 55 ]; therefore, the evaluation during the follow-up period of melanoma patients at different points is needed for a better antiganglioside profile characterization.…”

Section: Discussionmentioning

confidence: 99%

Antiganglioside Antibodies and Inflammatory Response in Cutaneous Melanoma

Ene

Tampa

Nicolae

et al. 2020

Journal of Immunology Research

View full text Add to dashboard Cite

Introduction. Endogenously produced antiganglioside antibodies could affect the evolution of cutaneous melanoma. Epidemiological and experimental evidence suggest “chronic inflammation” to be one of the hallmarks in skin cancers. The aim of the study was to characterize the relation between antiganglioside antibodies and inflammation in cutaneous melanoma focusing on gangliosides GM1, GM2, GM3, GD1a, GD1b, GT1b, GQ1b. Material and Method. We performed an observational study that included 380 subjects subdivided into three groups: patients with metastatic melanoma (170 cases), patients with primary melanoma (160 cases), and healthy subjects (50 subjects). The assessment of antiganglioside antibodies, IgG, and IgM classes, against -GM1, -GM2, -GM3, -GD1a, -GD1b, -GT1b, -GQ1b was performed using immunoblot technique (EUROLine kit). Results. The presence of IgG and IgM antiganglioside antibodies in primary melanoma was (%), as follows: anti-GM1 (5.0 and 13.1), -GM2 (1.8 and 18.1), -GM3 (0.6 and 5.6), -GD1a (0.6 and 15.0), -GD1b (3.7 and 10.7), -GT1b (0.0 and 13.1), -GQ1b (0.0 and 5.0). In metastatic melanoma, the level of antiganglioside antibodies was significantly lower compared with primary melanoma (p<0.05), while in the control group they were absent. Antiganglioside antibodies anti-GM1 and -GD1a were positively correlated, while anti-GM3, -GD1b, and -GT1b were negatively associated with the inflammatory markers, interleukin 8 (IL-8), and C reactive protein (CRP). Conclusions. Tumour ganglioside antigens generate an immune response in patients with primary melanomas. The host’s ability to elaborate an early antiganglioside response could be considered as a defence mechanism, directed toward eliminating a danger signal from the tumour microenvironment. Antiganglioside antibodies associated with inflammation markers could be used as diagnostic, monitoring, and treatment tools in patients with cutaneous melanoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Antiganglioside Antibodies and Inflammatory Response in Cutaneous Melanoma

Ene

Tampa

Nicolae

et al. 2020

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

“…Lymph node involvement is an important prognostic factor in the early stages [32,68]. Multiple pathways are activated in the process of tumorigenesis, metastasis and therapy resistance and phytochemicals have demonstrated beneficial effects both in the prevention and in the treatment of metastatic melanoma [15,40,53,63]. Fisetin limits melanoma cell invasiveness by modulating mitogen-activated protein kinase/extracellular signalregulated kinase 1/2 (MAPK/ERK) signalling and reducing the activation of nuclear factor-kappa B (NF-κB) pathway [41].…”

Section: Skin Melanomamentioning

confidence: 99%

Emerging Applications of Some Important Natural Compounds in the Field of Oncology

Scheau¹

2020

FARMACIA

View full text Add to dashboard Cite

Cancer is among the leading causes of death worldwide, with several malignancies presenting an increase in their incidence, such as thyroid cancer, hepatocellular carcinoma, skin melanoma, uterine cancer, and oral cavity cancer. Phytochemicals have long been used in various fields of medicine for their properties, and the discovery of anti-tumour, anti-oxidant, and anti-inflammatory effects of some of these substances have prompted their application in the field of oncology. Several in vivo and in vitro studies have demonstrated the effectiveness of some phytochemicals on specific tumour cell lines, revealing their potential role in the complementary treatment of cancer. This paper addresses the anti-tumour and chemopreventive roles of various phytochemicals in malignancies with increasing incidence. Rezumat Cancerul este una dintre cele mai frecvente cauze de mortalitate din lume, câteva dintre aceste patologii prezentând creșteri ale incidenței, cum ar fi cancerul tiroidian, carcinomul hepatocelular, melanomul cutanat, cancerul uterin și carcinomul cavității orale. Substanțele fitochimice au fost utilizate mult timp în diverse domenii ale medicinei pentru proprietățile lor, iar descoperirea efectelor anti-tumorale, anti-oxidante și anti-inflamatorii ale unora dintre aceste substanțe au încurajat utilizarea acestora în domeniul oncologiei. Unele studii in vivo și in vitro au demonstrat eficiența unor fitochimicale pe anumite linii celulare tumorale, evidențiind rolul lor potențial în tratamentul complementar al cancerului. Această lucrare se referă la rolurile anti-tumorale și chemopreventive ale diverselor fitochimicale în malignitățile cu incidență în creștere.

show abstract

“…We have shown on murine melanoma cell lines that exposure to high concentrations of epinephrine and norepinephrine induces a significant increase in cell proliferation (Caruntu(b) et al, 2014). There are different expression of specific receptors depending on the melanoma origin, thus in human melanoma cell lines we have shown that the proliferative action triggered by epinephrine and nor-epinephrine can be overridden by some of specific inhibitors (Surcel et al, 2018).…”

Section: Neuroendocrine "Influencers" Of Melanomagenesismentioning

confidence: 86%

Snapshot – changing melanocyte identity in melanoma developing route

Neagu¹,

Constantin²,

Engin³

et al. 2020

JOCI

View full text Add to dashboard Cite

The largest organ with immune function, the skin, has complex structure and various physiological functions. Cells comprising this complex structure sustain various processes and have proteomic/transcriptomic/genomic patterns that would subside to developing a specific function in a specific moment of time and in a defined space. Within the complex skin structure melanocyte is one of the cell types that is involved in skin’s main functions. In the process of normal melanocyte transformation into a neoplastic cell there are several stages that are favored by a protumor inflammatory milieu. A tumorigenesis-friendly environment would increase cell’s genetic instability that will further lead to tumorigenesis and additionally to metastasis. In the environment, immune cells and immune-related molecules seminally contribute to the inflammatory landscape. Melanomagenesis is not a straight forward process. In order to take place, various factors need to collide, environmental, genetic, and immune factors must conjoint. Melanomas are heterogeneous and the transformed melanocyte has various genetic alterations, these mutations being specific to the site, to the degree of UV exposure, and/or specific for the genetic make-up of the host’s organism. This variability suggests that melanoma has more than one causal pathway. Within our paper we will snapshot the cellular identity of normal melanocyte, through benign transformed melanocyte up to a full blown tumorigenesis. Factors that are triggering these transformations(s) will be briefly highlighted.

show abstract

Adrenergic Modulation of Melanoma Cells Proliferation

Cited by 7 publications

References 22 publications

Antiganglioside Antibodies and Inflammatory Response in Cutaneous Melanoma

Antiganglioside Antibodies and Inflammatory Response in Cutaneous Melanoma

Emerging Applications of Some Important Natural Compounds in the Field of Oncology

Snapshot – changing melanocyte identity in melanoma developing route

Contact Info

Product

Resources

About